Oral Delivery of Meglumine Antimoniate-β-Cyclodextrin Complex for Treatment of Leishmaniasis

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 1, 2004, Pages 100-103

  Demicheli, Cynthia ^a   Ochoa, Rosemary ^a   Da Silva, José B B ^a   Falcão, Camila A B ^b   Rossi Bergmann, Bartira ^b   De Melo, Alan L ^a   Sinisterra, Ruben D ^a   Frézard, Frédéric ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CYCLODEXTRIN; MEGLUMINE ANTIMONATE; PROTON; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; EXPERIMENTAL MODEL; FEMALE; LEISHMANIA; MOUSE; NONHUMAN; PARASITE; PRIORITY JOURNAL; RELAXATION TIME; SKIN LEISHMANIASIS;

ADMINISTRATION, ORAL; ANIMALS; ANTIPROTOZOAL AGENTS; BETA-CYCLODEXTRINS; CHEMISTRY, PHYSICAL; CYCLODEXTRINS; INJECTIONS, INTRAPERITONEAL; INTESTINAL ABSORPTION; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; MICE; MICE, INBRED BALB C; ORGANOMETALLIC COMPOUNDS;

EID: 0347361714     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.1.100-103.2004     Document Type: Article

References (14)

1. Berman, J. D. 1988. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev. Infect. Dis. 10:560-586.
2. Berman, J. D. 1997. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 24:684-703.
3. Demicheli, C., R. Ochoa, I. S. Lula, F. C. Gozzo, M. N. Eberlin, and F. Frézard. 2003. Pentavalent organoantimonial derivatives: two simple and efficient synthetic methods for meglumine antimonate. Appl. Organomet. Chem. 17:226-231.
4. Dietze, R., S. F. Carvalho, L. C. Valli, J. Berman, T. Brewer, W. Milhous, J. Sanchez, B. Schuster, and M. Grogl. 2001. Phase 2 trial of WR6026, as an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am. J. Trop. Med. Hyg. 65:685-689.
5. Hirayama, F., and K. Uekama. 1999. Cyclodextrin-based controlled drug release system. Adv. Drug Deliv. Rev. 36:125-141.
6. Irie, T., and K. Uekama. 1997. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 86:147-162.
7. Kayser, O., C. Olbrich, V. Yardley, A. F. Kiderlen, and S. L. Croft. 2003. Formulation of amphotericin B as nanosuspension for oral administration. Int. J. Pharm. 254:73-75.
8. Lindner, K., and W. Saenger. 1978. Beta-cyclodextrin dodecahydrate-crowding of water-molecules within a hydrophobic cavity. Angew. Chem. Int. Ed. Engl. 17:694-695.
9. Marsden, P. D. 1985. Pentavalent antimonials: old drug for new diseases. Rev. Soc. Bras. Med. Trop. 18:187-198.
10. Rossi-Bergmann, B., A. Lenglet, C. R. Bezerra-Santos, D. Costa-Pinto, and Y. M. Traub-Czeko. 1999. Use of fluorescent Leishmania for faster quantitation of parasite growth in vitro and in vivo. Mem. Inst. Oswaldo Cruz 94:74.
11. Schneider, H.-J., F. Hacket, and V. Rudiger. 1998. NMR studies of cyclodextrins and cyclodextrin complexes. Chem. Rev. 98:1755-1785.
12. Silva, J. B. B., M. B. O. Giacomelli, and A. J. Curtius. 1998. Iridium and rhodium as permanent chemical modifiers for the determination of Ag, As, Bi, Cd and Sb by electrothermal atomic absorption spectrometry. Microchem. J. 60:249-254.
13. Sundar, S., T. K. Jha, C. P. Thakur, J. Engel, H. Sindermann, C. Fisher, K. Junge, A. Bryceson, and J. Berman. 2002. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 347:1739-1746.
14. Uekama, K., F. Hiramaya, and T. Irie. 1998. Cyclodextrin drug carrier system. Chem. Rev. 98:2045-2076.